TC-510

· TCR2 Therapeutics

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for TC-510, covering 2025-08-27 to 2026-07-13. Get the full timeline:

Most recent: Clinical Trial Results: A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer [Phase 1, Phase 2]